Agenda

Session Introduction

‍

Novel Antiestrogen Agents and Dynamic ctDNA Monitoring for HR+/HER2- MBC

‍

Targeting the PI3K Pathway: Rational Drug Design and New Strategies

‍

After Endocrine Resistance: Antibody Drug Conjugates for Metastatic HR+ Breast Cancer

‍

Molecular Mechanisms of Stem-Cell Maintenance and HR+ Metastatic Progression

‍

Audience Q&A and Panel Discussion